Details of the Drug Combinations

General Information of This Drug (ID: DMQ8J0U)

Drug Name

Basmisanil DMQ8J0U

Synonyms

1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
Cognitive impairment	6D71	Phase 2	[2]
Complete androgen insensitivity syndrome	LD2A.4	Phase 2	[3]
Immune dysregulation	4A01.2	Phase 2	[3]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Basmisanil + Idarubicin	DCS2IM9	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age.
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.